论文部分内容阅读
目的观察利奈唑胺治疗医院获得性耐甲氧西林金黄色葡萄球菌(MRSA)肺炎的临床疗效及安全性。方法使用利奈唑胺治疗医院获得性MRSA肺炎58例,观察其临床疗效及安全性。结果利奈唑胺治疗的痊愈率为36.2%(21/58),有效率为67.2%(39/58),细菌清除率为65.5%(38/58),生存率为84.5%(49/58),病死率为15.5%(9/58)。其中确诊后用药组病死率为32.0%,经验性用药组病死率为3.0%,经验性用药组与确诊后用药组比较病死率明显较低(P=0.008)。不良反应发生率为3.5%(2/58),不良反应轻且不影响治疗。结论利奈唑胺治疗医院获得性MRSA肺炎疗效肯定,不良反应轻,可以作为重症患者治疗医院获得性MRSA肺炎的首选药物之一。
Objective To observe the clinical efficacy and safety of linezolid in the treatment of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Methods Linezolid was used to treat 58 cases of hospital-acquired MRSA pneumonia. The clinical efficacy and safety were observed. Results The cure rate of linezolid was 36.2% (21/58), the effective rate was 67.2% (39/58), the bacterial clearance rate was 65.5% (38/58) and the survival rate was 84.5% (49/58) The case fatality rate was 15.5% (9/58). After the diagnosis, the case-fatality rate was 32.0% in the medication group and the case-fatality rate in the empirical medication group was 3.0%. The mortality in the empirical medication group was significantly lower than that in the diagnosed medication group (P = 0.008). The incidence of adverse reactions was 3.5% (2/58), mild adverse reactions did not affect the treatment. Conclusion Linezolid is effective in treating hospital-acquired MRSA pneumonia and its adverse reactions are mild. It can be regarded as one of the first choice drugs for the treatment of hospital-acquired MRSA pneumonia in critically ill patients.